Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
Related press release
INDP similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement on Form S-1 (Nos. 333-269000 and 333-259771), the Registration Statements on Form S-3 (Nos. 333-267236 and 333-230016), and the Registration Statement on Form S-8 (No. 333-259127) of Indaptus Therapeutics, Inc. (the “Company”) of our report dated March 16, 2023, relating to our audits of the Company’s consolidated financial statements as of December 31, 2022 and 2021, and for each of the years then ended, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission.
/s/ Haskell & White LLP | |
HASKELL & WHITE LLP |
Irvine, California
March 16, 2023